Biosimilars in Oncology: From Development to Clinical Practice
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference46 articles.
1. NCCN biosimilars white paper: regulatory, scientific, and patient safety perspectives;Zelenetz;J Natl Compr Canc Netw,2011
2. The economic pressures for biosimilar drug use in cancer medicine;Cornes;Targ Oncol,2012
3. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer;Hurwitz;N Engl J Med,2004
4. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001
5. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours;Aapro;Eur J Cancer,2011
Cited by 52 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Obstacles to Biosimilar Acceptance and Uptake in Oncology;JAMA Oncology;2024-07-01
2. An Overview of Biosimilars—Development, Quality, Regulatory Issues, and Management in Healthcare;Pharmaceuticals;2024-02-11
3. Regulatory Considerations of Biosimilars in Cancer;Biosimilars for Cancer Treatment;2024
4. Patients’ perspectives on the relevance of biosimilars’ outcomes in oncology: qualitative study with nominal group technique;Supportive Care in Cancer;2023-11-27
5. A bibliometric analysis of research progress on pharmacovigilance and cancer from 2002 to 2021;Frontiers in Oncology;2023-01-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3